Kevan C. Herold

32.0k total citations · 12 hit papers
278 papers, 20.0k citations indexed

About

Kevan C. Herold is a scholar working on Genetics, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Kevan C. Herold has authored 278 papers receiving a total of 20.0k indexed citations (citations by other indexed papers that have themselves been cited), including 194 papers in Genetics, 154 papers in Endocrinology, Diabetes and Metabolism and 144 papers in Surgery. Recurrent topics in Kevan C. Herold's work include Diabetes and associated disorders (191 papers), Pancreatic function and diabetes (142 papers) and Diabetes Management and Research (134 papers). Kevan C. Herold is often cited by papers focused on Diabetes and associated disorders (191 papers), Pancreatic function and diabetes (142 papers) and Diabetes Management and Research (134 papers). Kevan C. Herold collaborates with scholars based in United States, Canada and United Kingdom. Kevan C. Herold's co-authors include Jeffrey A. Bluestone, George S. Eisenbarth, Stephen E. Gitelman, Carla J. Greenbaum, William Hagopian, Ann Marie Schmidt, Jay S. Skyler, Shi Fang Yan, Ravichandran Ramasamy and Jerry P. Palmer and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Kevan C. Herold

266 papers receiving 19.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetics, pathogenesis and clinical interventions in type 1 diabetes

2010 917 citations Jeffrey A. Bluestone, Kevan C. Herold et al. Nature profile →
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

2002 903 citations Kevan C. Herold, William Hagopian et al. profile →
Type 1 diabetes immunotherapy using polyclonal regulatory T cells

2015 810 citations Jeffrey A. Bluestone, Jane H. Buckner et al. Science Translational Medicine profile →
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

2015 735 citations Mark A. Atkinson, Peter A. Gottlieb et al. Diabetes Care profile →
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation

2005 670 citations Kevan C. Herold et al. profile →
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

1995 518 citations Kevan C. Herold et al. profile →
Control of TH17 cells occurs in the small intestine

2011 505 citations Jeffrey A. Bluestone, Kevan C. Herold et al. Nature profile →
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

2018 412 citations Zoe Quandt, Ana Luisa Perdigoto et al. Diabetes profile →
Immunotherapy: Building a bridge to a cure for type 1 diabetes

2021 137 citations Jeffrey A. Bluestone, Jane H. Buckner et al. profile →
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

2022 117 citations Emily K. Sims, Rachel Besser et al. Diabetes profile →
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes

2023 111 citations Colin Dayan, Lucienne Chatenoud et al. profile →
The immunology of type 1 diabetes

2024 81 citations Kevan C. Herold, Ana Luisa Perdigoto et al. profile →

Peers

Countries citing papers authored by Kevan C. Herold

Since Specialization

Citations

This map shows the geographic impact of Kevan C. Herold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevan C. Herold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevan C. Herold more than expected).

Fields of papers citing papers by Kevan C. Herold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevan C. Herold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevan C. Herold. The network helps show where Kevan C. Herold may publish in the future.

Co-authorship network of co-authors of Kevan C. Herold

This figure shows the co-authorship network connecting the top 25 collaborators of Kevan C. Herold. A scholar is included among the top collaborators of Kevan C. Herold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevan C. Herold. Kevan C. Herold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab 2025 ·Diabetes Care ·Chantal Mathieu, Emily K. Sims, Lucienne Chatenoud, Eddie A. James, Mark A. Atkinson, Kevan C. Herold	0
2	Humoral determinants of checkpoint immunotherapy 2025 ·Nature ·Yile Dai, (unknown), (unknown), (unknown), Jillian R. Jaycox, Joseph N. Cunningham, Eric Y. Wang, Lin Zhang, Suzanne Fischer, Sean M. Carroll, (unknown), Yuval Kluger, Kevan C. Herold, Leon Furchtgott, Harriet M. Kluger, Aaron M. Ring	3
3	CTLA-4 blockade shifts the B cell repertoire toward autoimmunity 2025 ·Journal of Clinical Investigation ·(unknown), Meng Wang, Yile Dai, Adrien Mirouse, (unknown), (unknown), (unknown), Ruchi Gera, (unknown), (unknown), Ana Luisa Perdigoto, (unknown), Christopher Massad, Antonietta Bacchiocchi, Aaron M. Ring, Yuval Kluger, Harriet M. Kluger, Kevan C. Herold, Eric Meffre	0
4	Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes 2024 ·Journal of Clinical Investigation ·(unknown), Paula Preston‐Hurlburt, (unknown), Pamela Clark, Peter S. Linsley, S. Alice Long, Can Liu, Galina Koroleva, Andrew J. Martins, John S. Tsang, Kevan C. Herold	17
5	Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes 2024 ·Diabetes ·Esther Latres, Carla J. Greenbaum, (unknown), Colin Dayan, Helen M. Colhoun, John M. Lachin, Jay S. Skyler, Michael R. Rickels, Simi Ahmed, Sanjoy Dutta, Kevan C. Herold, (unknown)	15
6	Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals 2024 ·The Journal of Clinical Endocrinology & Metabolism ·Emily K. Sims, David Cuthbertson, Laura M. Jacobsen, Heba M. Ismail, Brandon M. Nathan, Kevan C. Herold, María J. Redondo, Jay M. Sosenko	4
7	Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID ‐19 patients: Comparison with influenza and pre‐pandemic data 2023 ·Diabetes Obesity and Metabolism ·(unknown), (unknown), Stephen Wang, (unknown), Rebecca B. Jennings, Helen Tang, (unknown), (unknown), Roman Fleysher, (unknown), (unknown), Parsa Mirhaji, Wei Hou, Kevan C. Herold, Timothy Q. Duong	18
8	ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis 2023 ·Journal for ImmunoTherapy of Cancer ·Jacqueline E. Mann, Liliana E. Lucca, (unknown), Ross D. Merkin, Marie E. Robert, Badr Al‐Bawardy, Khadir Raddassi, (unknown), Nikhil S. Joshi, David A. Hafler, Clara Abraham, Kevan C. Herold, Harriet M. Kluger	6
9	Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis 2023 ·Journal of the Endocrine Society ·Zoe Quandt, Stephanie Kim, Javier Villanueva‐Meyer, (unknown), Arabella Young, (unknown), Jinoos Yazdany, Gabriela Schmajuk, Stephanie Rush, Elad Ziv, Ana Luisa Perdigoto, Kevan C. Herold, Melissa G. Lechner, Maureen A. Su, James Tyrrell, Jeffrey A. Bluestone, Mark S. Anderson, Umesh Masharani	19
10	A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab 2023 ·Diabetologia ·Chantal Mathieu, Alice Wiedeman, Karen Cerosaletti, S. Alice Long, (unknown), Laura G. Cooney, Joan Vermeiren, Silvia Caluwaerts, Karolien Van Huynegem, Lothar Steidler, (unknown), Pieter Rottiers, Gerald T. Nepom, Kevan C. Herold, (unknown)	38
11	Immune responses to gut bacteria associated with time to diagnosis and clinical response to T cell–directed therapy for type 1 diabetes prevention 2023 ·Science Translational Medicine ·(unknown), (unknown), Anthony Wong, (unknown), Kevan C. Herold, Jayne S. Danska	10
12	Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies 2023 ·Diabetes Care ·Jay M. Sosenko, David Cuthbertson, Emily K. Sims, Heba M. Ismail, Brandon M. Nathan, Laura M. Jacobsen, Mark A. Atkinson, Carmella Evans‐Molina, Kevan C. Herold, Jay S. Skyler, María J. Redondo, (unknown)	9
13	Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective breakdown → 2022 ·Diabetes ·Emily K. Sims, Rachel Besser, Colin Dayan, Cristy Geno Rasmussen, Carla J. Greenbaum, Kurt Griffin, William Hagopian, Mikael Knip, Anna E. Long, Frank B. Martin, Chantal Mathieu, Marian Rewers, Andrea K. Steck, John M. Wentworth, Stephen S. Rich, Olga Kordonouri, Anette‐Gabriele Ziegler, Kevan C. Herold, (unknown)	117
14	Quantifying the effect of experimental perturbations at single-cell resolution 2021 ·Nature Biotechnology ·Daniel B. Burkhardt, Jay S. Stanley, Alexander Tong, Ana Luisa Perdigoto, Scott Gigante, Kevan C. Herold, Guy Wolf, Antonio J. Giráldez, David van Dijk, Smita Krishnaswamy	84
15	The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes 2021 ·Diabetes ·Emily K. Sims, David Cuthbertson, Kevan C. Herold, Jay M. Sosenko	14
16	Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes 2021 ·Nature Communications ·Jinxiu Rui, Songyan Deng, Ana Luisa Perdigoto, Gerald Ponath, Romy Kursawe, Nathan Lawlor, Tomokazu S. Sumida, (unknown), Michael L. Stitzel, David Pitt, Jun Lü, Kevan C. Herold	19
17	The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes 2021 ·JCI Insight ·Shen Dong, Kamir J. Hiam-Galvez, Cody T. Mowery, Kevan C. Herold, Stephen E. Gitelman, Jonathan H. Esensten, Weihong Liu, Angela Lares, Ashley Leinbach, Michael Lee, Vinh Nguyen, Stanley Tamaki, Whitney Tamaki, (unknown), Morvarid Mehdizadeh, Amy Putnam, Matthew H. Spitzer, Chun Ye, Qizhi Tang, Jeffrey A. Bluestone	151
18	Natural mucosal barriers and COVID-19 in children 2021 ·JCI Insight ·Carl A. Pierce, Sharlene Sy, Benjamin Galen, D. Goldstein, Erika P. Orner, Marla J. Keller, Kevan C. Herold, Betsy C. Herold	89
19	Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients 2020 ·Science Translational Medicine ·Carl A. Pierce, Paula Preston‐Hurlburt, Yile Dai, Clare Burn Aschner, Natalia Cheshenko, Benjamin Galen, S. Garforth, Natalia G. Herrera, Rohit K. Jangra, Nicholas C. Morano, Erika P. Orner, Sharlene Sy, Kartik Chandran, James Dziura, Steven C. Almo, Aaron M. Ring, Marla J. Keller, Kevan C. Herold, Betsy C. Herold	213
20	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience 2018 ·Diabetes ·Carla J. Greenbaum, Cate Speake, Jeffrey P. Krischer, Jane H. Buckner, Peter A. Gottlieb, Desmond Schatz, Kevan C. Herold, Mark A. Atkinson	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact